SpeeDx has pioneered four proprietary multiplexing technologies that are transforming molecular diagnostics worldwide. Our innovative PCR technologies enable laboratories to do more with less—detecting multiple targets in a single test, reducing costs, accelerating time-to-result, and empowering clinicians to improve patient outcomes. From off-the-shelf products to custom development and technology partnering, we're your complete multiplexing solution, whether you’re targeting human, veterinary or beyond.
Four Powerful Technologies.
Infinite Possibilities.
SpeeDx has pioneered four proprietary multiplexing technologies that are transforming molecular diagnostics worldwide. Our innovative PCR technologies enable laboratories to do more with less—detecting multiple targets in a single test, reducing costs, and accelerating time-to-result. From off-the-shelf products to custom development and technology partnering, we're your complete multiplexing solution, whether you’re targeting human, veterinary or beyond.
Four Powerful Technologies.
Infinite Possibilities.
Why Multiplexing Matters for Your Lab
Significantly reduce testing costs by detecting numerous targets in a single reaction rather than running separate tests for each pathogen or genetic marker.
Cost Reduction
Improve time-to-result by multiplexing on a consolidated testing workflow delivering comprehensive diagnostic answers for many samples per run.
Faster Results
Provide comprehensive data supporting resistance-guided therapy and precision treatment pathways that improve cure rates, as shown with our M. genitalium assay which increased cure rates from 48% to 95%. [1,2]
Empower clinicians
Maximize existing qPCR platform investments by multiplexing more than twice the targets per well, compared to conventional approaches. As shown in the RespiV PlexPlus® 14 target test.
Laboratory Efficiency
Products
50+ Multiplexed Commercial Products globally – including IVDR, TGA, and Health Canada approved diagnostic assays for STI and respiratory testing, as well as additional specialized kits for gastrointestinal testing, and more. These off-the-shelf solutions are ready to deploy in your laboratory.
Technologies
We develop world-class multiplexing technologies, supported by 100+ patents. Do you want to integrate PlexPCR®, PlexPlus®, PlexPrime®, or InSignia® technologies into your own products? Our Technology Partnering services include licensing and Custom components.
Custom Solutions
Partner with us to create bespoke multiplexed assays tailored to your specific needs. Leverage our patented technologies, or any combination thereof, to differentiate your offering and address unmet needs in analyte detection and/or RNA expression.
What we do
Products
50+ Multiplexed Commercial Products globally – including research assays for STI, respiratory and GI testing, as well as additional specialized kits. These off-the-shelf solutions are ready to deploy in your laboratory.
Technologies
We develop world-class multiplexing technologies, supported by 100+ patents. Do you want to integrate PlexPCR®, PlexPlus®, PlexPrime®, or InSignia® technologies into your own products? Our Technology Partnering services include licensing and Custom
components.
Custom Solutions
Partner with us to create bespoke multiplexed assays tailored to your specific needs. Leverage our patented technologies, or any combination thereof, to differentiate your offering and address unmet needs in analyte detection and/or RNA expression.
What we do
The Future of Molecular Multiplexing
Multiplexing isn't just more efficient — it's transforming what's possible in diagnostics. SpeeDx has invested 15+ years and secured 100+ patents developing proprietary platforms that deliver unprecedented multiplexing capabilities. Our technologies power products used in hundreds of laboratories worldwide and enable diagnostic innovations that simply weren't possible with conventional approaches.
Whether you're a reference laboratory seeking off-the-shelf solutions, a diagnostic company building cutting-edge products, or a healthcare system requiring custom testing programs, SpeeDx provides the multiplexing expertise and proven technologies to bring your vision to market.
Proven at Scale
100+ direct customers globally, with 1000s more laboratories reached through our diagnostic company partnerships, or via distributors.
Regulatory Experience
Products listed under IVDR (including Class C), TGA, Health Canada; and quality assurance with ISO 13485 and MDSAP compliance.
Published Evidence
60+ peer-reviewed publications demonstrating clinical validity and analytical performance. SpeeDx pioneering AMR testing with ResistancePlus® MG first described in 2016. [3]
The Future of Molecular Multiplexing
Multiplexing isn't just more efficient - it creates endless possibilities for analyte detection. SpeeDx has invested 15+ years and secured 100+ patents developing proprietary platforms that deliver unprecedented multiplexing capabilities. Our technologies power products used in hundreds of laboratories worldwide and enable diagnostic innovations that simply weren't possible with conventional approaches.
Whether you're a reference laboratory seeking off-the-shelf solutions, a diagnostic company building cutting-edge products, or a healthcare system requiring custom testing programs, SpeeDx provides the multiplexing expertise and proven technologies to bring your vision to market.
Proven at Scale
100+ direct customers globally, with 1000s more laboratories reached through our diagnostic company partnerships, or via distributors.
Regulatory Experience
Products listed under IVDR (including Class C), TGA, Health Canada; and quality assurance with ISO 13485 and MDSAP compliance.
Published Evidence
60+ peer-reviewed publications demonstrating clinical validity and analytical performance. SpeeDx pioneering AMR testing with ResistancePlus®MG* first described in 2016. [3]
References:
1. Read et. al. Clin Infect Dis. 2019 Feb 1;68(4):554-560
2. Durukan et. al. Clin Infect Dis. 2020 Sep 12;71(6):1461-1468
3. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0156740
Footnote:
*ResistancePlus® products are not available in all regions. For options within your region please reach out to our team today.
References:
1. Read et. al. Clin Infect Dis. 2019 Feb 1;68(4):554-560
2. Durukan et. al. Clin Infect Dis. 2020 Sep 12;71(6):1461-1468
3. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0156740
Contact the Technology team?
SpeeDx offers the technology, expertise, and partnership models to accelerate your diagnostic success.